CCO Treatment Updates

Practice in Evolution: Optimal Management of Colorectal Cancer

Journal Article Reviews

Adding Cetuximab to a Bevacizumab-Containing Standard Chemotherapy Regimen in First-line Colorectal Cancer Decreases Efficacy: Results From the CAIRO2 Trial

Tol J, et al. NEJM. 2009;360:563-572.
Capsule Summary | Expert Commentary | Slides

Microsatellite Instability and Response to Adjuvant Therapy in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803

Bertagnolli MM, et al. J Clin Oncol. 2009;27:1814-1821.
Capsule Summary | Expert Commentary | Slides

Module

Cases Cubed: 3 Cases, 3 Expert Opinions in Colorectal Cancer

Program Chairs: Axel Grothey, MD, Nancy Roach

Faculty:

Axel Grothey, MD
Cathy Eng, MD
Richard M. Goldberg, MD

Nancy Roach

CREDIT INFORMATION

Release Date: 11/09/09

Expiration Date: 11/08/10

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: Please log in to view status

In this Expert Case Discussion, Axel Grothey, MD; Cathy Eng, MD; Richard M. Goldberg, MD; and Nancy Roach explore current thinking regarding the clinical management of patients with colorectal cancer in 3 case scenarios.

Learning Objectives

Upon completion of this activity, participants should be able to:

Incorporate evolving data on the targeted treatment of metastatic CRC into clinical practice to optimize patient outcomes
Apply predictive and prognostic tests in the clinical management of patients with CRC
Manage the adverse events associated with chemotherapeutic treatment of colorectal cancer
Interpret current data on adjuvant therapies for patients with CRC
Analyze the role of tumor KRAS mutation status as a predictor of response to anti-EGFR therapy in patients with metastatic CRC

CCO Slideset

Selected Currently Enrolling Phase II/III Clinical Trials in CRC

Download slides on currently enrolling phase II/III clinical trials in colorectal cancer.

Format: Microsoft PowerPoint (.ppt) | File size: 741 KB | Date posted: 11/13/2009

Video Module

Clinical Implications of Recent Data on the Community Oncologist

Program Chairs: Axel Grothey, MD, Nancy Roach

Faculty:

Al B. Benson III, MD, FACP

CREDIT INFORMATION

Release Date: 11/23/09

Expiration Date: 11/22/10

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: Please log in to view status

Al B. Benson, III, MD, FACP, discusses the impact of recent data in colorectal cancer including findings from the QUASAR validation study, NSABP C-08, ACCENT, STEPP, and other phase III trials on clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

Analyze the role of mismatch repair deficiency in determining therapy for patient with stage II or III colorectal cancer (CRC)
Interpret the role of bevacizumab as adjuvant therapy in patients with stage II or III CRC
Evaluate the relationship between KRAS status and anti-EGFR therapy
Appraise the use of prophylactic skin treatment in patients receiving anti-EGFR therapy
Assess the use of intravenous calcium and magnesium to prevent oxaliplatin-related neurotoxicity

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.